AU StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Cambium Bio Limited

0.350

+0.000

Volume:22.12K

Turnover:7.78K

Market Cap:4.95M

PE:-233.33

High:0.360

Open:0.360

Low:0.350

Close:0.350

Loading ...

Overview Company News Filings

BRIEF-Cambium Bio Says FDA Approves Elate Ocular Phase 3 Clinical Trial Protocol

Cambium Bio gains US FDA approval for Phase 3 Elate Ocular dry eye disease trial protocol

Cambium jumps 43% as FDA approves Phase 3 trial for Elate Ocular

The Market Herald

Cambium Bio Ltd - FDA Approves Elate Ocular® Phase 3 Clinical Trial Protocol

THOMSON REUTERS

Cambium Bio Ltd-Placement Shares Cleansing Notice

THOMSON REUTERS

BRIEF-Cambium Bio Says U.S. FDA Grants Fast Track Designation To Elate Ocular

Cambium Bio Ltd-FDA Grants Fast Track Designation

THOMSON REUTERS

Cambium Bio Successfully Closes a$3.0M Financing Round

THOMSON REUTERS

Press Release: Cambium Bio Successfully Closes A$3.0M Financing Round

BRIEF-Cambium Bio Requests Trading Halt Due To Proposed Capital Raising

Cambium Bio Ltd - Trading Halt Requested Due to Proposed Capital Raising Announcement

THOMSON REUTERS

BRIEF-Cambium Bio Says CEO Karolis Rosickas Has Acquired Additional 38,717 Shares Of Co

Cambium Bio Ltd - CEO Karolis Rosickas Has Acquired Additional 38,717 Shares of Co

THOMSON REUTERS

ATHA Energy Announces Option Agreements With Terra Uranium for Spire, Horizon, and Pasfield Projects

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/CMB.AU/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"CMB.AU"},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CMB.AU\",,,,,undefined,":{"symbol":"CMB.AU","market":"AU","secType":"STK","nameCN":"Cambium Bio Limited","latestPrice":0.35,"timestamp":1741233611148,"preClose":0.35,"halted":0,"volume":22121,"delay":0,"changeRate":0,"change":0,"floatShares":6241093,"shares":14143000,"eps":-0.0015,"lyrEps":-0.005504,"amount":7776,"amplitude":0.028571,"volumeRatio":0.737879,"dividePrice":0,"prevYearClose":0.4,"fiveDayClose":0.4,"twentyDayClose":0.37},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CMB.AU\",,,,,undefined,":{"symbol":"CMB.AU","floatShares":6241093,"roa":"--","roe":"--","lyrEps":-0.005504,"volumeRatio":0.737879,"shares":14143000,"dividePrice":0,"high":0.36,"amplitude":0.028571,"preClose":0.35,"low":0.35,"week52Low":0.004,"pbRate":"--","week52High":0.68,"institutionHeld":0,"latestPrice":0.35,"committee":0.992429,"eps":-0.0015,"divideRate":0,"volume":22121,"delay":0,"ttmEps":-0.0015,"open":0.36,"prevYearClose":0.4,"prevWeekClose":0.39,"prevMonthClose":0.39,"prevQuarterClose":0.4,"fiveDayClose":0.4,"twentyDayClose":0.37,"sixtyDayClose":0.625},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CMB.AU\",params:#limit:5,,,undefined,":[{"market":"AU","date":"2024-07-04","symbol":"CMB.AU","defaultRemindTime":1720051200000,"type":"split","dateTimestamp":1720015200000,"forFactor":100,"toFactor":1,"ratio":100}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CMB.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CMB.AU\",pageSize:16,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2514303111","title":"BRIEF-Cambium Bio Says FDA Approves Elate Ocular Phase 3 Clinical Trial Protocol","url":"https://stock-news.laohu8.com/highlight/detail?id=2514303111","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514303111?lang=en_us&edition=fundamental","pubTime":"2025-02-25 13:09","pubTimestamp":1740460163,"startTime":"0","endTime":"0","summary":"BRIEF-Cambium Bio Says FDA Approves Elate Ocular Phase 3 Clinical Trial ProtocolFeb 25 (Reuters) - Cambium Bio Ltd CMB.AX:FDA APPROVES ELATE OCULAR PHASE 3 CLINICAL TRIAL PROTOCOLFurther company coverage: CMB.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250225:nFWN3PF1YQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","CMB.AU"],"gpt_icon":0},{"id":"2514039295","title":"Cambium Bio gains US FDA approval for Phase 3 Elate Ocular dry eye disease trial protocol","url":"https://stock-news.laohu8.com/highlight/detail?id=2514039295","media":"Small Caps","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514039295?lang=en_us&edition=fundamental","pubTime":"2025-02-25 12:38","pubTimestamp":1740458334,"startTime":"0","endTime":"0","summary":"Cambium Bio  has received approval from the US Food and Drug Administration  for a protocol relating to Phase 3 clinical trials of its Elate Ocular treatment for moderate-to-severe dry eye disease.The approval represents a key milestone in advancing Elate Ocular towards market registration and follows the FDA granting the product fast-track designation in December.Fast-tracking helps expedite the review of drugs that treat serious conditions and address unmet medical needs.Chief executive officer Karolis Rosickas said the Phase 3 protocol was pivotal to the development of the Elate Ocular trials.“The trial design reflects extensive consultation with regulatory experts and key opinion leaders to ensure we meet FDA requirements for registration,” he said.The fast-track designation will enable Cambium to have more frequent interactions with the FDA throughout Elate Ocular’s development process and makes the product eligible for potential accelerated approvals and priority reviews.“With fa","market":"us","thumbnail":"https://cdn.shortpixel.ai/client/w_868,q_lossy,to_auto,ret_wait/https://150309019.v2.pressablecdn.com/wp-content/uploads/2025/02/Cambium-Bio-ASX-CMB-FDA-Approval-Elate-Ocular-Phase-3-Clinical-Trial-Protocol.jpg","type":0,"news_type":0,"thumbnails":["https://cdn.shortpixel.ai/client/w_868,q_lossy,to_auto,ret_wait/https://150309019.v2.pressablecdn.com/wp-content/uploads/2025/02/Cambium-Bio-ASX-CMB-FDA-Approval-Elate-Ocular-Phase-3-Clinical-Trial-Protocol.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://smallcaps.com.au/cambium-bio-us-fda-approval-phase-3-elate-ocular-dry-eye-disease-trial/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"smallcap_stock","symbols":["BK7067","CMB.AU"],"gpt_icon":0},{"id":"2514708970","title":"Cambium jumps 43% as FDA approves Phase 3 trial for Elate Ocular","url":"https://stock-news.laohu8.com/highlight/detail?id=2514708970","media":"The Market Herald","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514708970?lang=en_us&edition=fundamental","pubTime":"2025-02-25 08:37","pubTimestamp":1740443820,"startTime":"0","endTime":"0","summary":"Cambium Bio  has flagged approval from the U.S. FDA for phase three of a clinical trial using its Elate Ocular product to treat moderate to severe dry eye disease.The market clearly liked the news – Cambium jumped more than 40% in the second hour of trade; the latest winner in a small basket of biotech stocks progressing towards late-stage approvals and commercialisation.In Cambium’s own words, the Phase 3 trial represents a final step towards market registration for its Elate Ocular product, with the third trial typically being the final in the FDA’s approval ringer. The Phase 3 program is ultimately geared to acquire a Biologics Licence Application . Trial sites in both the U.S. and Australia – “and select other countries” – will constitute Phase 3; Cambium won FDA Fast Track designation for Elate last December.The material provided in this article is for information only and should not be treated as investment advice. Viewers are encouraged to conduct their own research and consult ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://themarketonline.com.au/cambium-jumps-43-as-fda-approves-phase-3-trial-for-elate-ocular-2025-02-25/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"markerherald_stock","symbols":["CMB.AU","BK7067"],"gpt_icon":0},{"id":"2514670775","title":"Cambium Bio Ltd -  FDA Approves Elate Ocular® Phase 3 Clinical Trial Protocol","url":"https://stock-news.laohu8.com/highlight/detail?id=2514670775","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514670775?lang=en_us&edition=fundamental","pubTime":"2025-02-25 07:15","pubTimestamp":1740438945,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250224:nFWN3PF1YQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CMB.AU","BK7067"],"gpt_icon":0},{"id":"2490825133","title":"Cambium Bio Ltd-Placement Shares Cleansing Notice","url":"https://stock-news.laohu8.com/highlight/detail?id=2490825133","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490825133?lang=en_us&edition=fundamental","pubTime":"2024-12-12 12:30","pubTimestamp":1733977836,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241212:nTUEGJDCY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","CMB.AU"],"gpt_icon":0},{"id":"2490926764","title":"BRIEF-Cambium Bio Says U.S. FDA Grants Fast Track Designation To Elate Ocular","url":"https://stock-news.laohu8.com/highlight/detail?id=2490926764","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490926764?lang=en_us&edition=fundamental","pubTime":"2024-12-09 09:13","pubTimestamp":1733706808,"startTime":"0","endTime":"0","summary":"BRIEF-Cambium Bio Says U.S. FDA Grants Fast Track Designation To Elate OcularDec 9 (Reuters) - Cambium Bio Ltd CMB.AX:FDA GRANTS FAST TRACK DESIGNATIONUS FDA GRANTS FAST TRACK DESIGNATION TO CAMBIUM BIO'S ELATE OCULARFurther company coverage: CMB.AX ((Reuters.Briefs@thomsonreuters.com;;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241209:nTUE28QH18:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","CMB.AU"],"gpt_icon":0},{"id":"2490591766","title":"Cambium Bio Ltd-FDA Grants Fast Track Designation","url":"https://stock-news.laohu8.com/highlight/detail?id=2490591766","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490591766?lang=en_us&edition=fundamental","pubTime":"2024-12-09 07:56","pubTimestamp":1733702207,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241208:nTUE28QH18:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CMB.AU","BK7067"],"gpt_icon":0},{"id":"2489105996","title":"Cambium Bio Successfully Closes a$3.0M Financing Round","url":"https://stock-news.laohu8.com/highlight/detail?id=2489105996","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489105996?lang=en_us&edition=fundamental","pubTime":"2024-12-05 11:58","pubTimestamp":1733371085,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241205:nTUA1CZPCK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","CMB.AU"],"gpt_icon":0},{"id":"2489105737","title":"Press Release: Cambium Bio Successfully Closes A$3.0M Financing Round","url":"https://stock-news.laohu8.com/highlight/detail?id=2489105737","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489105737?lang=en_us&edition=fundamental","pubTime":"2024-12-05 11:58","pubTimestamp":1733371080,"startTime":"0","endTime":"0","summary":"SYDNEY, Dec. 05, 2024  --  Cambium Bio Limited  , a clinical-stage regenerative medicine company focusing on the development of innovative biologics for ophthalmology and tissue repair applications, is pleased to announce the successful completion of a A$3.0 million capital raising.-- Capital raising of A$3.0 million completed at A$0.4637 per share,representing a 25% discount to the 5-day Volume Weighted Average Price. -- Strong support from new strategic investor AventaCell Biomedical Corp and. -- Additional participation from Cambium Bio directors, CEO, and Australian. -- Proceeds to advance Phase 3 clinical development of Elate Ocular for. The proceeds will primarily support the advancement of Elate Ocular through its registration-enabling Phase 3 clinical trials for dry eye disease, which are planned to commence in calendar Q2 2025. The funds will also provide working capital for the Company's ongoing operations.","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4022","R","CMB.AU","BK7067","BK4232"],"gpt_icon":0},{"id":"2488494026","title":"BRIEF-Cambium Bio Requests Trading Halt Due To Proposed Capital Raising","url":"https://stock-news.laohu8.com/highlight/detail?id=2488494026","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488494026?lang=en_us&edition=fundamental","pubTime":"2024-12-02 14:04","pubTimestamp":1733119490,"startTime":"0","endTime":"0","summary":"BRIEF-Cambium Bio Requests Trading Halt Due To Proposed Capital RaisingDec 2 (Reuters) - Cambium Bio Ltd CMB.AX:TRADING HALT REQUESTED DUE TO PROPOSED CAPITAL RAISING ANNOUNCEMENTFurther company coverage: CMB.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241202:nFWN3N3030:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","CMB.AU"],"gpt_icon":0},{"id":"2488649111","title":"Cambium Bio Ltd - Trading Halt Requested Due to Proposed Capital Raising Announcement","url":"https://stock-news.laohu8.com/highlight/detail?id=2488649111","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488649111?lang=en_us&edition=fundamental","pubTime":"2024-12-02 14:03","pubTimestamp":1733119413,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241202:nFWN3N3030:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","CMB.AU"],"gpt_icon":0},{"id":"2475308551","title":"BRIEF-Cambium Bio Says CEO Karolis Rosickas Has Acquired Additional 38,717 Shares Of Co","url":"https://stock-news.laohu8.com/highlight/detail?id=2475308551","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2475308551?lang=en_us&edition=fundamental","pubTime":"2024-10-15 14:09","pubTimestamp":1728972558,"startTime":"0","endTime":"0","summary":"Oct 15 (Reuters) - Cambium Bio Ltd   :   * CEO KAROLIS ROSICKAS HAS ACQUIRED ADDITIONAL 38,717 SHARES OF CO Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","market":null,"thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CMB.AU","BK7067"],"gpt_icon":0},{"id":"2475738513","title":"Cambium Bio Ltd - CEO Karolis Rosickas Has Acquired Additional 38,717 Shares of Co","url":"https://stock-news.laohu8.com/highlight/detail?id=2475738513","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2475738513?lang=en_us&edition=fundamental","pubTime":"2024-10-15 09:54","pubTimestamp":1728957285,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241015:nFWN3LQ0X7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","CMB.AU"],"gpt_icon":0},{"id":"2474183062","title":"ATHA Energy Announces Option Agreements With Terra Uranium for Spire, Horizon, and Pasfield Projects","url":"https://stock-news.laohu8.com/highlight/detail?id=2474183062","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2474183062?lang=en_us&edition=fundamental","pubTime":"2024-10-11 19:00","pubTimestamp":1728644400,"startTime":"0","endTime":"0","summary":"VANCOUVER, British Columbia, Oct. 11, 2024  -- ATHA Energy Corp.     is pleased to announce, in furtherance to its news release from August 20th, 2024 , the Company and Terra Uranium Ltd.   have executed a definitive option agreement for T92 to earn an option to acquire a 70% interest in ATHA’s Spire and Horizon properties  and a definitive option agreement for ATHA to earn an option to acquire up to a 60% interest in T92’s Pasfield Lake property .In accordance with the terms of the Option Agreement ATHA shall grant T92 the sole and exclusive right and option to acquire up to a 70% interest in the Spire Horizon Projects  in consideration for incurring a minimum of $4,750,000 exploration expenditures as set out below:. on or before September 21, 2025, T92 must incur additional statutory exploration expenditures of at least $1,000,000 ;In accordance with the terms of the Option Agreement, T92 shall grant to ATHA the four exclusive and separate rights and options to acquire undivided lega","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/QvgTN87.iuCU61yGwX1Z7g--~B/aD0yNDI7dz02NTA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/4ad732e90ee5abcdfbb0f65a1a334ef4","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/QvgTN87.iuCU61yGwX1Z7g--~B/aD0yNDI7dz02NTA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/4ad732e90ee5abcdfbb0f65a1a334ef4"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/atha-energy-announces-option-agreements-110000205.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["T92.AU","BK4197","SASKF","BK4156","SR","BK7067","BK7083","CMB.AU","ATHA","UEC","BK4007"],"gpt_icon":0}],"pageSize":16,"totalPage":1,"pageCount":1,"totalSize":14}]}}